Brain

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

Saturday, September 25, 2021 - 5:15pm

This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.

Key Points: 
  • This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs.
  • Notably, the research found that a change in clinical management once genetic results were received was reported by clinicians for nearly half of patients.
  • The full research presentation from Invitae included:
    Epilepsy genetic testing guides clinical management and helps improve patient outcomes.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the findings and implications of the study; and the value of genetic testing to guide clinical management and improve outcomes for epilepsy patients.

TMMWV Celebrates 25 Years, Nearly 20 Million Powertrains Built; Innovation, Advanced Manufacturing to Guide Future Production

Friday, September 24, 2021 - 3:00pm

"We are well positioned for the next 25 years as innovation and advanced manufacturing lead the way.

Key Points: 
  • "We are well positioned for the next 25 years as innovation and advanced manufacturing lead the way.
  • The only Toyota plant in North America that makes both engines and transmissions producing nearly 20 million powertrains since 1996.
  • Coinciding with the 25-year anniversary celebration, The Toyota USA Foundation awarded a $189,000 grant to West Virginia University Institute of Technology.
  • Shamaya Morris, a production group leader at TMMWV, said it is a smart investment for the future.

Todos Medical Reports Second Quarter 2021 Financial Results

Friday, September 24, 2021 - 2:36pm

New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the second quarter of 2021 ended June 30, 2021. 

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (Todos Medical) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results todayfor the second quarter of 2021 endedJune 30, 2021.
  • Revenues: Total revenue in the second quarter of 2021 was$1.7 million, a significant increase compared to revenue of $32,000in the second quarter of 2020.
  • Loss from Operations: The Company recorded an operating loss of$(1,662,0000)in the second quarter of 2021 compared to an operating loss of$(1.719,000)in the second quarter of 2020.
  • "While we achieved significant business milestones in the second quarter, we also witnessed several key improvements to our financial condition as well," saidDaniel Hirsch, CFO of Todos Medical.

UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders

Friday, September 24, 2021 - 2:01pm

We are very pleased to have received the support from our existing convertible note holders with this lockup agreement, said Gerald E. Commissiong, President & CEO.

Key Points: 
  • We are very pleased to have received the support from our existing convertible note holders with this lockup agreement, said Gerald E. Commissiong, President & CEO.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States.

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

Friday, September 24, 2021 - 2:00pm

Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.

Key Points: 
  • Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.
  • The purpose of the research agreement is to establish evidence of W-ENV expression on the transcriptional and protein level, to ascertain whether this protein can be a blood biomarker of neurological complications of long-haul COVID.
  • This research agreement complements the previously announced efforts in the long-haul COVID field that GeNeuro has launched in Europe with Fondation FondaMental and the CIRI (International Center for Infectiology Research, Lyon, France).
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

Hyper Vision Limited: How Augmented Reality is Improving Surgery

Friday, September 24, 2021 - 1:35pm

The Shenzhen-based technology start-up is changing the future of medical procedures by utilizing advances in augmented reality (AR) and artificial intelligence (AI) technology.

Key Points: 
  • The Shenzhen-based technology start-up is changing the future of medical procedures by utilizing advances in augmented reality (AR) and artificial intelligence (AI) technology.
  • By incorporating augmented reality surgical procedures, diagnosis accuracy and speed will all improve.
  • Hyper Vision Limited believes augmented reality has enormous potential in the healthcare industry.
  • The technology startup was founded on the promise of transforming the healthcare industry by eradicating all unnecessary medical mistakes through the adoption of augmented reality and artificial intelligence.

NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device

Friday, September 24, 2021 - 10:00am

Working with industrial partners, Yehs team has developed a 0.2-mm ultrasonic device, which can generate tornado-like ultrasonic vortex and create a strong turbulent around the thrombus, therefore increasing penetration of thrombolytic drugs and resulting in very effective thrombolysis.

Key Points: 
  • Working with industrial partners, Yehs team has developed a 0.2-mm ultrasonic device, which can generate tornado-like ultrasonic vortex and create a strong turbulent around the thrombus, therefore increasing penetration of thrombolytic drugs and resulting in very effective thrombolysis.
  • Yeh said that animal studies have shown results of 60% thrombus shrinkage in the mice brain after applying ultrasonic vortex for ten minutes, demonstrating the potential of fast treatment.
  • Yeh added that his team is also working on using ultrasonic vortex for noninvasive thrombolysis, which provides potential to treat embolisms in the brain.
  • Reflecting on how he first got interested in ultrasonic vortex, Yeh recalled that it was a family trip to a marine science museum ten years ago.

Medicenna Appoints Dr. John H. Sampson to its Board of Directors

Thursday, September 23, 2021 - 9:30pm

A total of 51.408% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

Key Points: 
  • A total of 51.408% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
  • Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines.
  • Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells.
  • Medicennas early-stage BiSKITs program, (Bifunctional SuperKine ImmunoTherapies)is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Reading Plus Announces Expanded Partnership with South Carolina’s Beaufort County School District

Thursday, September 23, 2021 - 3:11pm

WINOOSKI, Vt., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Reading Plus, an evidence-based online program that uses personalized instruction to improve students reading proficiency, today announced the expanded use of its platform within the Beaufort County School District in South Carolina.

Key Points: 
  • WINOOSKI, Vt., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Reading Plus, an evidence-based online program that uses personalized instruction to improve students reading proficiency, today announced the expanded use of its platform within the Beaufort County School District in South Carolina.
  • Beginning with the 2021-2022 school year, all middle and high school students within the district will have access to Reading Plus for the following three years.
  • Reading Plus provides individual, strategic support that increases the fluency of our readers, said Melissa Murray, director of literacy, Beaufort County School District.
  • Used by more than 1 million students, Reading Plus improves striving students reading proficiency by 2.0-2.5 grade levels in a single school year when used with fidelity.

Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com

Thursday, September 23, 2021 - 1:37pm

New York, NY, and Tel Aviv, ISRAEL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an expansion of its Tollovid® dietary supplement 3CL protease (MPro) inhibitor immune support product line with the launch of Tollovid Daily™ via subscription. The subscription model takes the hassle out of remembering to order Tollovid Daily on a monthly basis. 

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (Todos Medical) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an expansion of its Tollovid dietary supplement 3CL protease (MPro) inhibitor immune support product line with the launch of Tollovid Daily via subscription .
  • Both Tollovid and Tollovid Daily are 3CL protease inhibitors for immune support that have 60 caplets per bottle.
  • Tollovid Daily was designed as a twice-daily dosing schedule for people on the go that provides one month of daily immune support.
  • Tollovid Daily is an affordable immune support solutionwith mass market appeal, said Gerald Commission CEO of Todos Medical.